Members' Portal
Home
About
Who We Are
Project Team
The Consortium
Donor Support
Countries
Brazil
Cambodia
Ethiopia
Ghana
India
Indonesia
Kenya
Malawi
Mozambique
South Africa
Tanzania
Zimbabwe
Preventing TB
Why Prevention?
Target Populations
Short-Course Preventive Therapies
Community Engagement
Our Approach
PK and Safety Studies
Supply & Scale up of 3HP
Generating Evidence
Civil Society Engagement
Resources
Library
TPT Implementation Tools
Fact Sheets
Publications
Reports
Slide Sets
Latest News
Social Media Toolkits
Videos
Useful Links
Members’ Portal
Contact Us
Members' Portal
Home
About
Who We Are
Project Team
The Consortium
Donor Support
Countries
Brazil
Cambodia
Ethiopia
Ghana
India
Indonesia
Kenya
Malawi
Mozambique
South Africa
Tanzania
Zimbabwe
Preventing TB
Why Prevention?
Target Populations
Short-Course Preventive Therapies
Community Engagement
Our Approach
PK and Safety Studies
Supply & Scale up of 3HP
Generating Evidence
Civil Society Engagement
Resources
Library
TPT Implementation Tools
Fact Sheets
Publications
Reports
Slide Sets
Latest News
Social Media Toolkits
Videos
Useful Links
Members’ Portal
Contact Us
Useful Links
World TB Day Tools and Activities
NTCA Providers Guidance
Safety & PK of weekly rifapentine/isoniazid (3HP) in adults with HIV on dolutegravir. CROI 2019. Seattle. 4–7 March 2019. Oral abstract
Cytokine-mediated systemic adverse drug reactions in a drug-drug interaction study of dolutegravir with once-weekly isoniazid and rifapentine.
